Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,204.00
  • Today's Change-30.00 / -2.43%
  • Shares traded138.24k
  • 1 Year change-17.93%
  • Beta0.4832
Data delayed at least 20 minutes, as of Aug 09 2022 17:31 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Abcam PLC grew revenues 78.04% from 260.00m to 462.90m while net income improved 37.60% from 12.50m to 17.20m.
Gross margin71.21%
Net profit margin1.24%
Operating margin2.06%
Return on assets0.43%
Return on equity0.61%
Return on investment0.50%
More ▼

Cash flow in GBPView more

In 2021, cash reserves at Abcam PLC fell by 92.20m. Cash Flow from Financing totalled 126.40m or 27.31% of revenues. In addition the company generated 96.20m in cash from operations while cash used for investing totalled 313.70m.
Cash flow per share0.2007
Price/Cash flow per share61.69
Book value per share2.87
Tangible book value per share0.2495
More ▼

Balance sheet in GBPView more

Abcam PLC has a Debt to Total Capital ratio of 25.93%, a higher figure than the previous year's 17.45%.
Current ratio1.13
Quick ratio0.8189
Total debt/total equity0.3501
Total debt/total capital0.2593
More ▼

Growth rates in GBP

Growth rate information is not available.
Div yield(5 year avg)0.01%
Div growth rate (5 year)--
Payout ratio (TTM)0.00%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.